Related Experiment Video
Updated: May 31, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
As time goes by?: the fallacy of thrombolysis in STEMI networks
Wolfgang von Scheidt1, Christian Thilo
1Department of Internal Medicine I, Klinikum Augsburg, Heart Center Augsburg-Swabia, Germany. wolfgang.scheidt@klinikum-augsburg.de
Insights
Primary percutaneous coronary intervention (PPCI) is superior to thrombolysis (TL) for ST-elevation myocardial infarction (STEMI). Focus should be on timely PPCI availability, as prehospital TL offers no proven benefit over PPCI, even with delays.
Area of Science:
- Cardiology
- Emergency Medicine
- Interventional Cardiology
Background:
- ST-elevation myocardial infarction (STEMI) requires rapid reperfusion therapy.
- Primary percutaneous coronary intervention (PPCI) offers superior reperfusion rates (>90%) compared to thrombolysis (TL) (50%).
- TL's efficacy diminishes significantly after 2-3 hours from symptom onset.
Purpose of the Study:
- To compare the efficacy and prognostic benefits of PPCI versus TL in STEMI patients.
- To evaluate the impact of PCI-related delay (PRD) on treatment decisions.
- To determine optimal reperfusion strategies in STEMI management.
Main Methods:
- Comparative analysis of PPCI and TL based on existing data and registries.
- Assessment of reperfusion rates and patient outcomes.
- Evaluation of prehospital TL versus PPCI in STEMI management.
Main Results:
- PPCI demonstrates superior reperfusion and prognostic benefits over TL, even with significant delays.
- Prehospital TL has not shown a significant advantage over PPCI in any patient subgroup.
- A PCI-related delay (PRD) of 90-120 minutes indicates PPCI's prognostic superiority.
Conclusions:
- Efforts should prioritize ensuring PPCI availability within 2 hours for STEMI patients.
- Prehospital TL is a viable option only when PPCI facilities are unavailable within the recommended timeframe.
- Well-organized myocardial infarction networks are crucial for optimizing PPCI accessibility and STEMI outcomes.
Abstract:
Primary percutaneous coronary intervention (PPCI) is superior to thrombolysis (TL) as reperfusion therapy in ST-elevation myocardial infarction (STEMI). TL is a rapidly available, but semi-effective therapy (effective reperfusion in 50% of patients only), whereas PPCI is a potentially delayed, but highly effective therapy (effective reperfusion in >90%). Since TL loses its efficacy beyond 2-3 h after symptom onset, it is a significant reperfusion alternative to PPCI in early presenters only. The individual decision to treat an early presenter with PPCI or TL requires the evaluation of the time delay between potential start of TL or PPCI, the PCI-related delay (PRD). PRD is greatest, if TL is given in the prehospital setting. Until now, prehospital TL as the most rapidly available reperfusion strategy has failed to demonstrate any prognostic or even any other relevant benefit compared to PPCI in any subgroup of patients, even with time delays for PPCI of up to several hours. On average, a median PRD of at least 90-120 min can be considered a time corridor of prognostic superiority of PPCI over TL. This is already achieved in contemporary registries and myocardial infarction networks.Therefore, the efforts should not focus on the implementation of a dual reperfusion strategy (PPCI, and prehospital TL in selected cases) in established or upcoming myocardial infarction networks, but concentrate on the availability of PPCI in less than 2 h. TL, as rapid as possible, i.e. prehospital, is a vital treatment option in case of non-existing PPCI facilities within a median time limit of 2 h or even more, a scenario not existing or easily to eliminate in European countries by implementing well organized myocardial infarction networks. This is the mission to be accomplished.
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Venous Thrombosis I: Introduction
Ischemic Stroke ll: Pathophysiology
Clot Retraction and Fibrinolysis

